Therapy response with diffusion MRI: An update

Cancer Imaging

Volumn 12, Issue 2, 2012, Pages 395-402

  Bainsa, Lauren J ^a   Zweifel, Martin ^a   Thoenya, Harriet C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

ADC; Diffusion weighted MRI; Oncology; Treatment response

Indexed keywords

CONTRAST MEDIUM;

ADVANCED CANCER; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL DENSITY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; OSTEOSARCOMA; PROSTATE CANCER; RADIOFREQUENCY ABLATION; RECTUM CARCINOMA; REVIEW; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; WHOLE BODY IMAGING;

EID: 84867920206     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.9047     Document Type: Review

References (81)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. doi:10.3322/caac.20107. PMid:21296855.
2. Heijmen L, Verstappen MC, Ter Voert EE, et al. Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit Rev Oncol Hematol 2012; 83: 194-207. doi:10.1016/j.critrevonc.2011.12.008. PMid:22269446.
3. Malayeri AA, El Khouli RH, Zaheer A, et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. Radiographics 2011; 31: 1773-1791. doi:10.1148/rg.316115515. PMid:21997994.
4. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32: 2-16. doi:10.1002/jmri.22167. PMid:20575076.
5. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intra-voxel incoherent motion MR imaging. Radiology 1988; 168: 497-505. PMid:3393671.
6. Zhang JL, Sigmund EE, Chandarana H, et al. Variability of renal apparent diffusion coefficients: limitations of the monoexponential model for diffusion quantification. Radiology 2010; 254: 783-792. doi:10.1148/radiol.09090891. PMid:20089719.
7. Riches SF, Hawtin K, Charles-Edwards EM, de Souza NM. Diffusion-weighted imaging of the prostate and rectal wall: comparison of biexponential and monoexponential modelled diffusion and associated perfusion coefficients. NMR Biomed 2009; 22: 318-325. doi:10.1002/nbm.1328. PMid:19009566.
8. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125. PMid:19186405.
9. Thoeny HC, De Keyzer F, King AD. Diffusion-weighted MR imaging in the head and neck. Radiology 2012; 263: 19-32. doi:10.1148/radiol.11101821. PMid:22438440.
10. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-308. doi:10.1016/S0140-6736(02)09520-X. PMid:12147376.
11. Jang KM, Kim SH, Choi D, Lee SJ, Park MJ, Min K. Pathological correlation with diffusion restriction on diffusion-weighted imaging in patients with pathological complete response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results. Br J Radiol 2012. doi:10.1259/bjr/24557556. PMid:22422387.
12. Kremser C, Judmaier W, Hein P, Griebel J, Lukas P, de Vries A. Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol 2003; 179: 641-9. doi:10.1007/s00066-003-1045-9. PMid:14628131.
13. Messiou C, Collins DJ, Giles S, de Bono JS, Bianchini D, de Souza NM. Assessing response in bone metastases in prostate cancer with diffusion-weighted MRI. Eur Radiol 2011; 21: 2169-2177. doi:10.1007/s00330-011-2173-8. PMid:21710270.
14. Sala E, Kataoka MY, Priest AN, et al. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology 2012; 263: 149-159. doi:10.1148/radiol.11110175. PMid:22332064.
15. Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010; 20: 1703-1704. doi:10.1007/s00330-010-1734-6. PMid:20179939.
16. Galban CJ, Mukherji SK, Chenevert TL, et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2009; 2: 184-190. PMid:19701503.
17. King AD, Mo FK, Yu KH, et al. Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response. Eur Radiol 2010; 20: 2213-2220. doi:10.1007/s00330-010-1769-8. PMid:20309553.
18. Li XR, Cheng LQ, Liu M, et al. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol 2011; 29: 425-431. doi:10.1007/s12032-011-9842-y. PMid:21286861.
19. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: 843-847. doi:10.1016/j.mri.2005.11.005. PMid:16916701.
20. Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257: 56-63. doi:10.1148/radiol.10092021. PMid:20851939.
21. Shin HJ, Baek HM, Ahn JH, et al. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS. NMR Biomed 2012. doi:10.1002/nbm.2807. PMid:22566277.
22. Fangberget A, Nilsen LB, Hole KH, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 2011; 21: 1188-1199. doi:10.1007/s00330-010-2020-3. PMid:21127880.
23. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 2010; 49: 354-360. doi:10.3109/02841861003610184. PMid:20397769.
24. Woodhams R, Kakita S, Hata H, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging-comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 2010; 254: 357-366. doi:10.1148/radiol.2542090405. PMid:20093508.
25. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22: 104-113. doi:10.1002/nbm.1245. PMid:18384182.
26. Tozaki M, Oyama Y, Fukuma E. Preliminary study of early response to neoadjuvant chemotherapy after the first cycle in breast cancer: comparison of (1)H magnetic resonance spectroscopy with diffusion magnetic resonance imaging. Jpn J Radiol 2010; 28: 101-109. doi:10.1007/s11604-009-0391-7. PMid:20182844.
27. Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007; 25: 1-13. doi:10.1016/j.mri.2006.09.006. PMid:17222711.
28. Chang Q, Wu N, Ouyang H, Huang Y. Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy. Clin Imaging 2012; 36: 98-103. doi:10.1016/j.clinimag.2011.07.002. PMid:22370130.
29. Okuma T, Matsuoka T, Yamamoto A, Hamamoto S, Nakamura K, Inoue Y. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol 2009; 82: 989-994. doi:10.1259/bjr/13217618. PMid:19470575.
30. Yabuuchi H, Hatakenaka M, Takayama K, et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology 2011; 261: 598-604. doi:10.1148/radiol.11101503. PMid:21852569.
31. Ohno Y, Koyama H, Yoshikawa T, et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol 2012; 198: 75-82. doi:10.2214/AJR.11. 6525. PMid:22194481.
32. Liu Y, Bai R, Sun H, Liu H, Zhao X, Li Y. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 2009; 64: 1067-1074. doi:10.1016/j.crad.2009.07.010. PMid:19822239.
33. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004; 6: 831-837. doi:10.1593/neo.03343. PMid:15720810.
34. Marugami N, Tanaka T, Kitano S, et al. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. Cardiovasc Interv Radiol 2009; 32: 638-646. doi:10.1007/s00270-009-9532-8.
35. Schraml C, Schwenzer NF, Clasen S, et al. Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging 2009; 29: 1308-16. doi:10.1002/jmri.21770. PMid:19418557.
36. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900. doi:10.1148/radiol.2483071407. PMid:18710982.
37. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. Am J Roentgenol 2007; 188: 1001-1008. doi:10.2214/AJR.06.0601. (Pubitemid 46496932)
38. Anzidei M, Napoli A, Zaccagna F, et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr 2011; 35: 690-696. doi:10.1097/RCT.0b013e318230d905. PMid:22082538.
39. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JFH. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009; 250: 466-473. doi:10.1148/radiol.2502072222. PMid:19188315.
40. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009; 193: 1044-1052. doi:10.2214/AJR.08.1461. PMid:19770328.
41. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009; 15: 526-532. doi:10.1097/PPO.0b013e3181c5214b. PMid:20010173.
42. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 2011; 260: 752-761. doi:10.1148/radiol.11102330. PMid:21771960.
43. Sahin H, Harman M, Cinar C, Bozkaya H, Parildar M, Elmas N. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging. J Vasc Interv Radiol 2012; 23: 241-247. doi:10.1016/j.jvir.2011.08.030. PMid:22019180.
44. Goshima S, Kanematsu M, Kondo H, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 2008; 27: 834-839. doi:10.1002/jmri.21316. PMid:18383261.
45. Yu JS, Kim JH, Chung JJ, Kim KW. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging 2009; 30: 153-160. doi:10.1002/jmri.21818. PMid:19557734.
46. Baunin C, Schmidt G, Baumstarck K, et al. Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results. Skeletal Radiol 2012; 41: 1141-1149.
47. Oka K, Yakushiji T, Sato H, Hirai T, Yamashita Y, Mizuta H. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol 2010; 39: 141-146. doi:10.1007/s00256-009-0830-7. PMid:19924412.
48. Dudeck O, Zeile M, Pink D, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008; 27: 1109-1113. doi:10.1002/jmri.21358. PMid:18425832.
49. Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 2006; 16: 2637-2643. doi:10.1007/s00330-006-0342-y. PMid:16909220.
50. Thoeny HC, Forstner R, De Keyzer F. Genitourinary applications of diffusion-weighted MR imaging in the pelvis. Radiology 2012; 263: 326-342. doi:10.1148/radiol.12110446. PMid:22517953.
51. McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA. Diffusion-weighted MRI in cervical cancer. Eur Radiol 2008; 18: 1058-1064. doi:10.1007/s00330-007- 0843-3. PMid:18193428.
52. Chopra S, Verma A, Kundu S, et al. Evaluation of diffusion-weighted imaging as a predictive marker for tumor response in patients undergoing chemoradiation for postoperative recurrences of cervical cancer. J Cancer Res Ther 2012; 8: 68-73. doi:10.4103/0973-1482.95177. PMid:22531517.
53. Liu Y, Bai RJ, Sun HR, Liu HD, Wang DH. Diffusion-weighted magnetic resonance imaging of uterine cervical cancer. J Comput Assist Tomogr 2009; 33: 858-862. doi:10.1097/RCT.0b013e31819e93af. PMid:19940650.
54. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008; 111: 213-220. doi:10.1016/j.ygyno.2008.07. 048. PMid:18774597.
55. Kyriazi S, Collins DJ, Messiou C, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion coefficients. Radiology 2011; 261: 182-192. doi:10.1148/radiol.11110577. PMid:21828186.
56. Yoshida S, Koga F, Kobayashi S, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012; 83: e21-e27. doi:10.1016/j.ijrobp.2011.11.065. PMid:22414281.
57. Yoshida S, Koga F, Kawakami S, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75: 387-391. doi:10.1016/j.urology.2009.06.111. PMid:19914691.
58. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009; 29: 391-397. doi:10.1002/jmri.21645. PMid:19161194.
59. Song I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. Am J Roentgenol 2010; 194: W477-W482. doi:10.2214/AJR.09.3557.
60. Nemoto K, Tateishi T, Ishidate T. Changes in diffusion-weighted images for visualizing prostate cancer during antiandrogen therapy: preliminary results. Urol Int 2010; 85: 421-426. doi:10.1159/000321233. PMid:21051871.
61. Arumainayagam N, Kumaar S, Ahmed HU, et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 2010; 106: 991-997. doi:10.1111/j.1464-410X.2010.09291.x. PMid:20230392.
62. Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 2008; 190: 1180-1186. doi:10.2214/AJR.07. 2924. PMid:18430829.
63. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15: 986-994. doi:10.1158/1078-0432.CCR-08-1287. PMid:19188170.
64. Katahira K, Takahara T, Kwee TC, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 2010; 21: 188-196. doi:10.1007/s00330-010-1883-7. PMid:20640899.
65. Giannarini G, Nguyen DP, Thalmann GN, Thoeny HC. Diffusion-weighted magnetic resonance imaging detects local recurrence after radical prostatectomy: initial experience. Eur Urol 2012; 61: 616-620. doi:10.1016/j.eururo.2011.11. 030. PMid:22137601.
66. Park MJ, Kim SH, Lee SJ, Jang KM, Rhim H. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy. Radiology 2011; 260: 771-780. doi:10.1148/radiol.11102135. PMid:21846762.
67. Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010; 254: 170-178. doi:10.1148/radiol. 2541082230. PMid:20019139.
68. DeVries AF, Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 958-965. doi:10.1016/S0360-3016(03)00208-6. PMid:12829130.
69. Kim SH, Lee JY, Lee JM, Han JK, Choi BI. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol 2011; 21: 987-995. doi:10.1007/s00330-010- 1989-y. PMid:20978768.
70. Barbaro B, Vitale R, Valentini V, et al. Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 594-599. PMid:22099033.
71. Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009; 253: 116-125. doi:10.1148/radiol.2532090027. PMid:19789256.
72. Curvo-Semedo L, Lambregts DM, Maas M, Beets GL, Caseiro-Alves F, Beets-Tan RG. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging 2012; 35: 1365-1371. doi:10.1002/jmri.23589. PMid:22271382.
73. Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010; 39: 333-343. doi:10.1007/s00256-009-0789-4. PMid:20205350.
74. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009; 30: 298-308. doi:10.1002/jmri.21858. PMid:19629984.
75. Goudarzi B, Kishimoto R, Komatsu S, et al. Detection of bone metastases using diffusion-weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy. Magn Reson Imaging 2010; 28: 372-379. doi:10.1016/j.mri.2009.12.008. PMid:20106624.
76. Heusner TA, Kuemmel S, Koeninger A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010; 37: 1077-1086. doi:10.1007/s00259-010-1399-z. PMid:20204355.
77. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010; 20: 2027-2038. doi:10.1007/s00330-010-1758-y. PMid:20309558.
78. Kwee TC, van Ufford H, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 2009; 44: 683-690. doi:10.1097/RL-I-.0b013e3181afbb36. PMid:19724232.
79. Li S, Xue HD, Li J, et al. Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma. Chin Med Sci J 2008; 23: 138-144. doi:10.1016/S1001-9294(09)60028-6. PMid:18853847.
80. Kwee TC, Fijnheer R, Ludwig I, et al. Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma. Br J Haematol 2010; 149: 628-630. doi:10.1111/j.1365-2141.2010.08093.x. PMid:20128795.
81. Reischauer C, Froehlich JM, Koh DM, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 2010; 257: 523-531. doi:10.1148/radiol.10092469. PMid:20829534.